Medlab nanotech statins
October 23, 2015
Statins and insulins are among
the first drugs to be tested for
viabiity of nanotechnology-delivery
in human trials by Sydney-based,
ASX listed, biopharmaceutical
company, Medlab Clinical Ltd.
The company announced that it
has received ethics approval for the
trials, starting with atorvastatin and
an insulin compound.
Because the molecules are not
being changed, they can bypass
animal models and move directly to
Phase 0 human trials, Medlab ceo
Sean Hall said.
Medlab will apply its Nanocelle
drug delivery system to the
medications, with the platform
involving converting off-patent
pharmaceuticals into nanoparticle
form with a view to developing new
patented compounds.
“Through the NanoCelle
platform delivery mechanism, a
fraction of the normal dosage is
administered, bypassing oral intake
and gastrointestinal absorption,
which could lead to considerable
reduction in pain or other side
effects usually associated with the
drugs,” Hall said.
Nanocelle was previously
developed for Medlab’s Cannabis
research, and is key to delivering
less of the atorvastatin or insulin
compound, bypassing stomach
or intestinal absorption, and
producing a repeatable therapeutic
dose by way of a spray in the buccal
area of the mouth.
Medlab said having now received
ethics approval it expects to start
the trials next month.
The above article was sent to subscribers in Pharmacy Daily's issue from 23 Oct 15To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Oct 15
